

10/567754

IAP5 Rec'd PCT/PTO 10 FEB 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Akinori ARIMURA : Mail Stop: PCT

Serial No. NEW : Attorney Docket No. 2006-0134A

Filed February 10, 2006 :

NOVEL USE OF
CANNABINOID RECEPTOR AGONIST
[Corresponding to PCT/JP2004/011745
Filed August 16, 2004] : THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicant requests consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- each U.S. Patent and U.S. Patent application publication;
- each reference previously cited in the international application PCT/_____; and/or
- each reference previously cited in prior parent application Serial No. _____

1a. This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

10/567754

IAP5 Rec'd PCT/PTO 10 FEB 2008

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) the certification of paragraph 2 below is provided, **or**
(2) the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

10/567754


IAPS Rec'd PCT/PTO 10 FEB 2006

3. Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. a full or partial English language translation submitted herewith,
 - b. a foreign patent office search report (International Search Report) (in the English language) submitted herewith,
 - c. the concise explanation contained in the specification of the present application at pages 1-2,
 - d. the concise explanation set forth in the attached English language abstract,
 - e. the concise explanation set forth below or on a separate sheet attached to the reference:
5. A foreign patent office search report (International Search Report) citing one or more of the references is enclosed.

Respectfully submitted,

Akinori ARIMURA

By:


Michael R. Davis

Registration No. 25,134
Attorney for Applicant

MRD/pth
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
February 10, 2006

FORM PTO 1449 (modified)

ATTY DOCKET NO.
2006-0134ASERIAL NO.
NEWU.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: February 10, 2006

APPLICANT
Akinori ARIMURAFILING DATE
February 10, 2006

10/567754

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	6,818,640	11/2004	Hanasaki et al.			
AB	6,916,806	7/2005	Kai et al.			
AC	2004/0082619	4/2004	Tada et al.			
AD	5,532,237	7/1996	Gallant et al.			
AE	6,956,033	10/2005	Ogawa et al.			
AF	2003/0232855	12/2003	Iwamura et al.			
AG	2004/0044051	3/2004	Kozlowski et al.			
AH	6,509,352	1/2003	Inaba et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
AI	99/02499	1/1999	WO			
AJ	01/19807	3/2001	WO			
AK	02/072562	9/2002	WO			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	Annick de Vries et al., "The role of sensory nerve ending in nerve growth factor-induced airway hyperresponsiveness to histamine in guinea-pigs", British Journal of Pharmacology, Vol. 134, pages 771-776, 2001.
AM	Ester Fride, "Cannabinoids and Cystic Fibrosis: A Novel Approach to Etiology and Therapy", Journal of Cannabis Therapeutics, 2(1), pages 59-71, 2002.
AN	Gabriel G. Nahas et al., "The Reims Symposium (1978)", Marijuana and Medicine, New York, pages 13-24, March 20-21, 1998.
AO	J.D.P. Graham et al., "Bronchodilator Action of Extract of Cannabis and Δ^1 -Tetrahydrocannabinol", Pharmacology of Marijuana, Vol. 1, pages 269-276, 1976.
AP	Donald P. Tashkin et al., "Effects of Smoked Marijuana in Experimentally Induced Asthma", American Review of Respiratory Disease, 112(3), pages 377-386, 1975.

EXAMINER /Craig Ricci/

DATE CONSIDERED

06/12/2008

EXAMINER: Initial if reference considered or information furnished. If not applicable, initial and attach separate sheet. Initial and attach separate sheet if communication is to be forwarded to applicant. Initial and attach separate sheet if communication is to be forwarded to applicant.

PREFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: Y.O.R./

1A5 REC'D PCT/PTO 10 FEB 2006

FORM PTO 1449 (modified)

ATTY DOCKET NO.
2006-0134ASERIAL NO.
NEW

10/567754

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: February 10, 2006

APPLICANT
Akinori ARIMURAFILING DATE
February 10, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER
INITIALDOCUMENT
NUMBER

DATE

NAME

CLASS

SUBCLASS

FILING DATE IF
APPROPRIATE

BA

BB

BC

BD

BE

BF

BG

BH

BI

FOREIGN PATENT DOCUMENTS

DOCUMENT
NUMBER

DATE

COUNTRY

CLASS

SUBCLASS

TRANSLATION
YES NO

BJ

02/053543

7/2002

WO

BK

10-508870

9/1998

Japan

BL

02/10135

2/2002

WO

BM

BN

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

BO

BP

BQ

EXAMINER

/Craig Ricci/

DATE CONSIDERED

06/11/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./